If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

Free Content The efficacy of chloroquine, sulfadoxine–pyrimethamine and a combination of both for the treatment of uncomplicated Plasmodium falciparum malaria in an area of low transmission in western Uganda

You have access to the full text article on a website external to ingentaconnect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Download Article:

Abstract:

Summary

We conducted an efficacy study of chloroquine (CQ), sulfadoxine–pyrimethamine (SP) and a combination of both (SP + CQ) for the treatment of uncomplicated malaria in an area of low transmission with low drug pressure. On day 3, fever clearance was 97.4% (95% CI, 86.8–99.9), 100% (95% CI, 87.2–100) and 96.6% (95% CI, 82.2–99.9) in the CQ, SP and SP + CQ groups, respectively, (P = 0.65). On day 14, clinical success was 92.5% (95% CI, 79.6–98.4), 100% (95% CI, 87.2–100) and 100% (95% CI, 88.1–100) in the CQ, SP and CQ + SP groups, respectively. Clinical failure was seen in 7.5% with 5% (95% CI, 0.61–16.9) early treatment failure and 2.5% (95% CI, 0.06–13.2) late treatment failure of cases in the CQ group and 0% in the SP and SP + CQ groups. Parasitological resistance was observed at RI level in 10% (95% CI, 2.8–23.7), 18.5% (95% CI, 6.3–38.1) and 6.9% (95% CI, 0.85–22.8) for the CQ, SP and SP + CQ, respectively (P = 0.37). There was no age-dependent difference in clinical failure or parasitological resistance in any of the treatment groups and prior CQ use within the last 2 weeks did not affect CQ treatment outcome. The findings of this study suggest that CQ is still effective for the treatment of uncomplicated malaria in this area of low transmission and SP. However, combination therapy of SP + CQ is recommended to delay the development SP resistance, and regular surveillance for emerging CQ and SP resistance is needed to plan for alternative antimalarial drug regimens.

Keywords: Plasmodium falciparum; Uganda; chloroquine; clinical failure; low transmission; malaria; sulfadoxine–pyrimethamine

Document Type: Research Article

DOI: http://dx.doi.org/10.1046/j.1365-3156.2003.01167.x

Affiliations: 1:  Vector Control Division, Ministry of Health, Kampala, Uganda 2:  Danish Bilharziasis Laboratory, Charlottenlund, Denmark

Publication date: January 1, 2004

Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more